🇺🇸 FDA
Pipeline program

ATG-010 and ATG-008

ATG-008&010-DLBCL-001

Phase 1 other terminated

Quick answer

ATG-010 and ATG-008 for Relapsed/Refractory Diffuse Large B-cell Lymphoma is a Phase 1 program (other) at Shanghai Antengene Corporation Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Shanghai Antengene Corporation Limited
Indication
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase
Phase 1
Modality
other
Status
terminated

Clinical trials